Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm DeCamp, Aakash P Desai, Thomas J Dilling, Jonathan Dowell, Gregory A Durm, Scott Gettinger, Travis E Grotz, Matthew A Gubens, Aditya Juloori, Rudy P Lackner, Michael Lanuti, Jules Lin, Billy W Loo, Christine M Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C Mullikin, Thomas Ng, Dawn Owen, Dwight H Owen, Sandip P Patel, Tejas Patil, Patricio M Polanco, Jonathan Riess, Theresa A Shapiro, Aditi P Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C Yang, Edwin Yau, Kristina M Gregory, Lisa Hang
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers...
May 2024: Journal of the National Comprehensive Cancer Network: JNCCN